Parsa Kiai Purchases 43,150 Shares of Medifast (NYSE:MED) Stock

Medifast Inc (NYSE:MED) Director Parsa Kiai purchased 43,150 shares of Medifast stock in a transaction dated Thursday, August 20th. The stock was bought at an average price of $11.60 per share, for a total transaction of $500,540.00. Following the completion of the transaction, the director directly owned 661,306 shares in the company, valued at $7,671,149.60. The trade was a 6.98% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Parsa Kiai also recently made the following trade(s):

• On Wednesday, August 19th, Parsa Kiai acquired 29,337 shares of Medifast stock. The stock was bought at an average price of $11.66 per share, with a total value of $342,069.42.

Medifast Trading Up 3.3%

NYSE:MED opened at $12.00 on Friday. Medifast Inc has a 1-year low of $9.22 and a 1-year high of $14.67. The business’s 50-day moving average price is $10.92 and its two-hundred day moving average price is $11.06. The firm has a market capitalization of $134.16 million, a price-to-earnings ratio of -5.15 and a beta of 0.65.

Medifast (NYSE:MED) last issued its earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.37. The firm had revenue of $76.38 million for the quarter, compared to analysts’ expectations of $72.70 million. Medifast had a negative return on equity of 6.69% and a negative net margin of 8.08%.Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. Sell-side analysts predict that Medifast Inc will post -1 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Zacks Research cut shares of Medifast from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 11th. Weiss Ratings upgraded shares of Medifast from a “sell (e+)” rating to a “sell (d)” rating in a report on Monday, August 17th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Medifast has an average rating of “Reduce” and a consensus price target of $12.00.

Institutional Investors Weigh In On Medifast

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Amundi increased its holdings in Medifast by 43.5% during the 1st quarter. Amundi now owns 30,439 shares of the specialty retailer’s stock worth $398,000 after purchasing an additional 9,224 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of Medifast by 14.5% in the 1st quarter. AQR Capital Management LLC now owns 199,750 shares of the specialty retailer’s stock valued at $2,693,000 after purchasing an additional 25,366 shares during the period. Strs Ohio bought a new stake in shares of Medifast in the first quarter valued at about $78,000. JPMorgan Chase & Co. lifted its holdings in shares of Medifast by 2.5% in the second quarter. JPMorgan Chase & Co. now owns 53,341 shares of the specialty retailer’s stock valued at $749,000 after purchasing an additional 1,316 shares in the last quarter. Finally, Prudential Financial Inc. acquired a new position in shares of Medifast during the second quarter worth about $200,000. 95.51% of the stock is currently owned by institutional investors and hedge funds.

About Medifast

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.